Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

STRONG-HF Analysis Quantifies Gains From Rapid Uptake of GDMT

Todd Neale

May 08, 2025

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

Early, Intense GDMT Improves Decongestion in Acute HF: STRONG-HF

Todd Neale

July 19, 2024

News Daily News

Long-term Digoxin Use Linked to VT/VF Risk in HF Patients

L.A. McKeown

June 11, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

Todd Neale

March 25, 2024

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

Advertisement

STRONG-HF Analysis Quantifies Gains From Rapid Uptake of GDMT

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Early, Intense GDMT Improves Decongestion in Acute HF: STRONG-HF

Long-term Digoxin Use Linked to VT/VF Risk in HF Patients

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

Vast Majority of HFrEF Patients Eligible for Vericiguat

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content